Montelukast Krka (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor type 1 (CysLT1), preventing leukotriene D4 and related mediators from binding. This inhibition reduces bronchial smooth‑muscle contraction, vascular permeability, mucus secretion, and inflammatory cell recruitment in the airways, thereby decreasing edema and hyper‑responsiveness associated with asthma and allergic conditions.

The specific dose of Montelukast Krka is determined by the prescribing clinician based on the patient’s age, weight, severity of disease, and response to therapy. Dosage forms are typically tablets taken once daily in the evening, but the exact strength and regimen must follow the prescriber’s written order and local labeling requirements.

Safety data for montelukast in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus. Regarding breastfeeding, montelukast is excreted in milk in small amounts; a healthcare provider should evaluate the risk‑benefit balance before continuation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Montelukast Krka. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details and assists with any required import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids and long‑acting β‑agonists. It is particularly useful for patients with aspirin‑exacerbated respiratory disease or those who prefer a once‑daily tablet. While it may be less potent than inhaled steroids for severe asthma, it provides additional control of allergic symptoms and can be combined with other controller medications under medical supervision.

Montelukast Krka tablets should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protected from moisture, heat and direct sunlight. Do not store in the bathroom or near a kitchen sink. Ensure the product is kept out of reach of children and unused tablets are discarded after the expiration date.

Montelukast Krka is administered orally, usually as a tablet taken with or without food. The usual practice is to take the dose in the evening to align with the circadian pattern of leukotriene production, but the exact timing should follow the prescriber’s instructions. Swallow the tablet whole; do not crush or chew unless specifically directed by a healthcare professional.

The most serious risks linked to montelukast include neuropsychiatric events such as depression, anxiety, suicidal thoughts, and rare allergic reactions like anaphylaxis or severe skin eruptions (e.g., Stevens‑Johnson syndrome). Hepatic dysfunction manifested by elevated liver enzymes may also occur. Patients should be monitored closely for any mood changes, rash, or signs of liver injury, and medical attention should be sought promptly if serious symptoms develop.

Montelukast Krka should not be used in individuals with known hypersensitivity to montelukast or any component of the tablet formulation. It is also contraindicated in patients who have experienced severe allergic reactions to leukotriene‑modifying agents. Caution is advised in patients with active liver disease, and it should be avoided in pregnant women unless the potential benefit outweighs the risk, as determined by a qualified healthcare provider.